175 related articles for article (PubMed ID: 20597872)
1. Vision-related function after low-dose transpupillary thermotherapy versus photodynamic therapy for neovascular age-related macular degeneration.
Odergren A; Algvere PV; Seregard S; Libert C; Kvanta A
Acta Ophthalmol; 2010 Jun; 88(4):426-30. PubMed ID: 20597872
[TBL] [Abstract][Full Text] [Related]
2. Improved vision-related function after ranibizumab vs photodynamic therapy: a randomized clinical trial.
Bressler NM; Chang TS; Fine JT; Dolan CM; Ward J;
Arch Ophthalmol; 2009 Jan; 127(1):13-21. PubMed ID: 19139332
[TBL] [Abstract][Full Text] [Related]
3. A prospective randomised study on low-dose transpupillary thermotherapy versus photodynamic therapy for neovascular age-related macular degeneration.
Odergren A; Algvere PV; Seregard S; Kvanta A
Br J Ophthalmol; 2008 Jun; 92(6):757-61. PubMed ID: 18356266
[TBL] [Abstract][Full Text] [Related]
4. Vision-related function after ranibizumab treatment by better- or worse-seeing eye: clinical trial results from MARINA and ANCHOR.
Bressler NM; Chang TS; Suñer IJ; Fine JT; Dolan CM; Ward J; Ianchulev T;
Ophthalmology; 2010 Apr; 117(4):747-56.e4. PubMed ID: 20189654
[TBL] [Abstract][Full Text] [Related]
5. Full macular translocation (FMT) versus photodynamic therapy (PDT) with verteporfin in the treatment of neovascular age-related macular degeneration: 2-year results of a prospective, controlled, randomised pilot trial (FMT-PDT).
Lüke M; Ziemssen F; Völker M; Altpeter E; Beutel J; Besch D; Bartz-Schmidt KU; Gelisken F
Graefes Arch Clin Exp Ophthalmol; 2009 Jun; 247(6):745-54. PubMed ID: 19214552
[TBL] [Abstract][Full Text] [Related]
6. A prospective study on different methods for the treatment of choroidal neovascularization. The efficacy of verteporfin photodynamic therapy, intravitreal bevacizumab and transpupillary thermotherapy in patients with neovascular age-related macular degeneration.
Nowak MS; Jurowski P; Grzybowski A; Goś R; Pastuszka M; Kapica A; Śmigielski J
Med Sci Monit; 2012 Jun; 18(6):CR374-80. PubMed ID: 22648253
[TBL] [Abstract][Full Text] [Related]
7. Responsiveness of NEI VFQ-25 to changes in visual acuity in neovascular AMD: validation studies from two phase 3 clinical trials.
Suñer IJ; Kokame GT; Yu E; Ward J; Dolan C; Bressler NM
Invest Ophthalmol Vis Sci; 2009 Aug; 50(8):3629-35. PubMed ID: 19255158
[TBL] [Abstract][Full Text] [Related]
8. Photodynamic therapy with verteporfin following transpupillary thermotherapy for CNV evolving from an initially occult to a predominantly classic form, in patients with AMD.
Hamon F; Goeminne P
Semin Ophthalmol; 2001 Dec; 16(4):223-32. PubMed ID: 15513445
[TBL] [Abstract][Full Text] [Related]
9. [Transpupillary thermotherapy and age-related macular degeneration].
Desmettre T; Meunier I; Maurage CA; Mordon S
J Fr Ophtalmol; 2004 Nov; 27(9 Pt 2):3S57-64. PubMed ID: 15602407
[TBL] [Abstract][Full Text] [Related]
10. A pilot trial for comparison of photodynamic therapy and transpupillary thermotherapy for the management of classic subfoveal choroidal neovascularization secondary to age-related macular degeneration.
Tewari HK; Prakash G; Azad RV; Talwar D; Kai S
Indian J Ophthalmol; 2007; 55(4):277-81. PubMed ID: 17595476
[TBL] [Abstract][Full Text] [Related]
11. Improved vision-related function after ranibizumab treatment of neovascular age-related macular degeneration: results of a randomized clinical trial.
Chang TS; Bressler NM; Fine JT; Dolan CM; Ward J; Klesert TR;
Arch Ophthalmol; 2007 Nov; 125(11):1460-9. PubMed ID: 17998507
[TBL] [Abstract][Full Text] [Related]
12. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study.
Brown DM; Michels M; Kaiser PK; Heier JS; Sy JP; Ianchulev T;
Ophthalmology; 2009 Jan; 116(1):57-65.e5. PubMed ID: 19118696
[TBL] [Abstract][Full Text] [Related]
13. Transpupillary thermotherapy for occult subfoveal choroidal neovascularization: a 1-year, prospective randomized pilot study.
Gustavsson C; Agardh E
Acta Ophthalmol Scand; 2005 Apr; 83(2):148-53. PubMed ID: 15799724
[TBL] [Abstract][Full Text] [Related]
14. Full macular translocation versus photodynamic therapy with verteporfin in the treatment of neovascular age-related macular degeneration: 1-year results of a prospective, controlled, randomised pilot trial (FMT-PDT).
Gelisken F; Voelker M; Schwabe R; Besch D; Aisenbrey S; Szurman P; Grisanti S; Herzau V; Bartz-Schmidt KU
Graefes Arch Clin Exp Ophthalmol; 2007 Aug; 245(8):1085-95. PubMed ID: 17219106
[TBL] [Abstract][Full Text] [Related]
15. Verteporfin photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration.
Kaiser PK; ; Boyer DS; Garcia R; Hao Y; Hughes MS; Jabbour NM; Kaiser PK; Mieler W; Slakter JS; Samuel M; Tolentino MJ; Roth D; Sheidow T; Strong HA
Ophthalmology; 2009 Apr; 116(4):747-55, 755.e1. PubMed ID: 19243834
[TBL] [Abstract][Full Text] [Related]
16. Triamcinolone acetonide as adjunctive treatment to verteporfin in neovascular age-related macular degeneration: a prospective randomized trial.
Chaudhary V; Mao A; Hooper PL; Sheidow TG
Ophthalmology; 2007 Dec; 114(12):2183-9. PubMed ID: 18054638
[TBL] [Abstract][Full Text] [Related]
17. Low power vs standard power transpupillary thermotherapy in patients with age-related macular degeneration and subfoveal choroidal neovascularization ineligible for photodynamic therapy.
Hogan AC; Kilmartin DJ
Eye (Lond); 2006 Jun; 20(6):649-54. PubMed ID: 16082398
[TBL] [Abstract][Full Text] [Related]
18. Quality of life in a prospective, randomised pilot-trial of photodynamic therapy versus full macular translocation in treatment of neovascular age-related macular degeneration--a report of 1 year results.
Lüke M; Ziemssen F; Bartz-Schmidt KU; Gelisken F
Graefes Arch Clin Exp Ophthalmol; 2007 Dec; 245(12):1831-6. PubMed ID: 17347809
[TBL] [Abstract][Full Text] [Related]
19. Combination therapy with low-dose transpupillary thermotherapy and intravitreal ranibizumab for neovascular age-related macular degeneration: a 24-month prospective randomised clinical study.
Söderberg AC; Algvere PV; Hengstler JC; Söderberg P; Seregard S; Kvanta A
Br J Ophthalmol; 2012 May; 96(5):714-8. PubMed ID: 22241923
[TBL] [Abstract][Full Text] [Related]
20. Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results.
Kaiser PK; Brown DM; Zhang K; Hudson HL; Holz FG; Shapiro H; Schneider S; Acharya NR
Am J Ophthalmol; 2007 Dec; 144(6):850-857. PubMed ID: 17949673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
